Policlinico Universitario
- Address
- lock Available on a paid plan
Policlinico Universitario - Nephrology Research Center
Policlinico Universitario is a distinguished academic medical center actively engaged in advancing treatments for complex renal disorders. The institution demonstrates particular expertise in IgA Nephropathy (IgAN), a chronic kidney disease characterized by immunoglobulin A deposits in the glomeruli, contributing to progressive kidney damage.
- Immunoglobulin A Nephropathy (IgAN) therapeutic interventions
- Novel biologic agents for glomerular diseases
- Proteinuria reduction strategies in chronic kidney disease
The center's research portfolio includes Phase 3 clinical trials evaluating innovative monoclonal antibody therapies such as sibeprenlimab, focusing on measurable outcomes like urine protein-to-creatinine ratio (uPCR) reduction. Their work combines standard-of-care protocols with cutting-edge biologic interventions to improve long-term outcomes for patients with progressive kidney diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Policlinico Universitario
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase III | Not Recruiting | Nov 2022 | May 2026 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sibeprenlimab | 1 | Unknown | 2022-11-03 | 2022-11-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.